Medscape www.medscape.com

References for:
Stress-Dose Corticosteroid Therapy for Sepsis and Acute Lung Injury or Acute Respiratory Distress Syndrome in Critically Ill Adults

[Pharmacotherapy 22(9):1140-1156, 2002. © 2002 Pharmacotherapy Publications]


  1. American College of Chest Physicians-Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
  2. Angus DC, Linde-Zwirble WT, Lidisker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
  3. Rangel-Frausta MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;273:117-23.
  4. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia: United States, 1979-1987. JAMA 1990;263:937-8.
  5. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers: academic medical center consortium sepsis project working group. JAMA 1997;278:234-40.
  6. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001;29:S109-16.
  7. Bernard GR, Artigas A, Brigham KL, et al. The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Resp Crit Care Med 1994;149:818-24.
  8. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.
  9. Meduri GU. The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J 1996;9:2650-70.
  10. Pola MD, Navarrete-Navarro P, Rivera R, Fernandez-Mondejar E, Hurtado B, Vazquez-Mata G. Acute respiratory distress syndrome: resource use and outcomes in 1985 and 1995, trends in mortality and comorbidities. J Crit Care 2000;15:91-6.
  11. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997;111:1306-21.
  12. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001;29:S99-106.
  13. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-13.
  14. Fein AM, Calalang-Colussi MG. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock. Crit Care Clin 2000;16:289-317.
  15. Ihle BU. Adrenocortical response and cortisone replacement in systemic inflammatory response syndrome. Anaesth Intensive Care 2001;29:155-62.
  16. Spijkstra JJ, Girbes ARJ. The continuing story of corticosteroids in the treatment of septic shock. Intensive Care Med 2000;26:496-500.
  17. Annane D. Corticosteroids for septic shock. Crit Care Med 2001;29:S117-20.
  18. Lamberts SWJ, Bruining HA, De Jong FH. Corticosteroid therapy in severe illness. N Engl J Med 1997;337:1285-92.
  19. Walker BR, Williams BC. Corticosteroids and the vascular tone: mapping the messenger maze. Clin Sci 1992;82:597-605.
  20. Hollenberg SM, Cunnion RE. Endothelial and vascular smooth muscle function in sepsis. J Crit Care 1994;9:262-80.
  21. Spangelo BL, Gorospe WC. Role of cytokines in the neuroendocrine-immune system axis. Front Neuroendocrinol 1995;16:1-22.
  22. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-62.
  23. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med 1993;329:1246-53.
  24. Imura H, Fukata J. Endocrine-paracrine interaction in communication between the immune and endocrine systems: activation of the hypothalamic pituitary-adrenal axis in inflammation. Eur J Endocrinol 1994;130:32-7.
  25. Hermus AR, Sweep CG. Cytokines and the hypothalamic-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1990;37:867-71.
  26. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984;5:25-44.
  27. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor k B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998;24:1131-8.
  28. Bohrer H, Qui F, Zimmernann T, et al. Role of NF-kB in the mortality of sepsis. J Clin Invest 1997;100:972-85.
  29. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticosteroids: inhibition of NF-kB activity through induction of IkB synthesis. Science 1995;270:286-90.
  30. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-k B by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-53.
  31. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of the transcription factor NF-kB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994;91:752-6.
  32. McKay LI, Cidlowski JA. Cross-talk between nuclear factor k-B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 1998;12:45-56.
  33. Auphan N, Didonato JA, Helmberg A, Rosette C, Karin M. Immunoregulatory genes and immunosuppression by glucocorticoids. Arch Toxicol Suppl 1997;19:87-95.
  34. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I k B a in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
  35. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995;152:S125-42.
  36. Detera-Wadleigh SD, Karl M. The glucocorticoid receptor gene. Ann Intern Med 1993;119:1113-24.
  37. Damas P, Ledoux D, Nys M, et al. Cytokine serum levels during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1192;215:356-62.
  38. Calandra T, Gerain J, Heumann D, et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1191;91:23-9.
  39. Pinski MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock: relation to multiple-organ failure and mortality. Chest 1993;103:265-75.
  40. Riche FC, Cholley BP, Panis YH, et al. Inflammatory response in patients with septic shock secondary to generalized peritonitis. Crit Care Med 2000;28:433-7.
  41. Casey LC, Balk RS, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
  42. Antonelli M, Raponi GM, Martino P, et al. High IL-6 serum levels are associated with septic shock and mortality in septic shock patients with severe leukopenia due to hematological malignancies. Scand J Infect Dis 1995;27:381-4.
  43. Arnalich F, Lopez J, Codoceo R, Jimnez M, Madero R, Montiel C. Relationship of plasma leptin to plasma cytokines and human survival in sepsis and septic shock. J Infect Dis 1999;180:908-11.
  44. Arnalich F, Garcia-Palomero E, Lopez J, et al. Predictive value of nuclear factor kB activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000;68:1942-5.
  45. Dofferhoff AS, Bom VJ, de Vries-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20:185-92.
  46. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-a and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997;25:1813-19.
  47. Presterl E, Staudinger T, Pettermann M, et al. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med 1997;156:825-32.
  48. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts poor outcome in ARDS: plasma IL-1b and IL-6 are consistent and efficient markers of outcome over time. Chest 1995;107:1062-73.
  49. Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:602-11.
  50. Steinberg KP, Milberg JA, Martin TR, Maunder RJ, Cockrill BA, Hudson LD. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994;150:113-22.
  51. Baughman RP, Gunther KL, Rashkin MC, Keeton DA, Pattishall EN. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. Am J Respir Crit Care Med 1996;154:76-81.
  52. Kiehl MG, Ostermann H, Thomas M, Muller C, Cassens U, Kienast J. Inflammatory mediators in the bronchoalveolar lavage fluid and plasma in leukopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med 1998;26:1194-9.
  53. Roumen RM, Hendriks T, van der Ven-Jongekrijk J, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma: relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;218:769-76.
  54. Hatherill M, Tibby SM, Turner C, Ratnavel N, Murdoch IA. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit Care Med 2000;28:2591-4.
  55. Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164:1896-903.
  56. Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and the decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with adult respiratory distress syndrome. Ann Intern Med 1996;125:191-6.
  57. Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med 2001;163:1520-3.
  58. Ligtenberg JJM, Girbes ARJ, Beentjes JAM, Tulleken JE, van der Werf TS, Zijlstra JG. Hormones in the critically ill patient: to intervene or not to intervene. Intensive Care Med 2001;27:1567-77.
  59. Span LF, Hermus AR, Bartelink AK, et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992;18:93-6.
  60. Vermes I, Beishuizen A, Hampsink RM, Haanen C. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 1995;80:1238-42.
  61. Schroeder S, Wishers M, Klingmuller D, et al. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001;29:310-16.
  62. Ananne D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-45.
  63. Soni A, Pepper GM, Wyrwinski PM, et al. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995;98:266-71.
  64. Aygen B, Inan M, Doganay M, Kelestimur F. Adrenal function in patients with sepsis. Exp Clin Endocrinol Diabetes 1997;105:182-6.
  65. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337:582-3.
  66. Jurney TH, Cockrell JL Jr, Lindberg JS, Lamiell JM, Wade CE. Spectrum of serum cortisol response to ACTH in ICU patients: correlation with degree of illness and mortality. Chest 1987;92:292-5.
  67. Jarek MJ, Legare EJ, McDermott MT, Merenich JA, Kollef MH. Endocrine profiles for outcome prediction from the intensive care unit. Crit Care Med 1993;21:543-50.
  68. Drucker D, McLaughlin J. Adrenocortical dysfunction in acute medical illness. Crit Care Med 1986;14:789-91.
  69. Sibbald WJ, Short A, Cohen MP, Wilson RF. Variations in adrenocortical responsiveness during severe bacterial infections: unrecognized adrenocortical insufficiency in severe bacterial infections. Ann Surg 1977;186:29-33.
  70. Schein RM, Sprung CL, Marcial E, Napolitano L, Chernow B. Plasma cortisol levels in patients with septic shock. Crit Care Med 1990;18:259-63.
  71. Bouachour G, Tirot P, Gouello JP, Mathieu E, Vincent JF, Alquier P. Adrenocortical function during septic shock. Intensive Care Med 1995;21:57-62.
  72. Finlay WEI, McKee JI. Serum cortisol levels in severely stressed patients [letter]. Lancet 1982;1:1414-15.
  73. McKee JI, Finlay WEI. Cortisol replacement in severely stressed patients [letter]. Lancet 1983;1:484.
  74. Briegel J, Schelling G, Haller M, Mraz W, Forst H, Peter K. A comparison of the adrenocortical response during septic shock and after complete recovery. Intensive Care Med 1996;22:894-9.
  75. Vadas P, Pruzanski W, Stefanski E, et al. Concordance of endogenous cortisol and phospholipase A2 levels in gram-negative septic shock: a prospective study. J Lab Clin Med 1988;111:584-90.
  76. Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 1995;23:78-83.
  77. Moran JL, Chapman MJ, O'Fathartaigh MS, Peisach AR, Pannall PR, Leppard P. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med 1994;20:489-95.
  78. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Am J Respir Crit Care Med 2002;165:983-91.
  79. Meduri GU. Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? Chest 1998;114:355-9.
  80. Gaillard RC, Turnill D, Sappino P, Muller AF. Tumor necrosis factor a inhibits the hormonal response to the pituitary gland to hypothalamic releasing factors. Endocrinology 1990;127:101-6.
  81. Reincke M, Allolio B, Wurth G, Winkelmann W. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 1993;77:151-6.
  82. Hammond GL. Potential functions of plasma steroid-binding proteins. Trends Endocrinol Metab 1995;152:S125-42.
  83. Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and free cortisol index during septic shock and multitrauma. Intensive Care Med 2001;27:1584-91.
  84. Pugeat M, Bonneton A, Perrot D, et al. Decreased immuno-reactivity and binding activity of corticosteroid-binding globulin in serum in septic shock. Clin Chem 1989;35: 1675-9.
  85. Savu L, Zouaghi H, Carli A, Nunez EA. Serum depletion of corticosteroid binding activities: an early marker of human septic shock. Biochem Biophysical Res Comm 1981;102:411-19.
  86. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of dominant negative b isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 2001;98:6865-70.
  87. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB. Abrogation of glucocorticosteroid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-g. J Immunol 1991;146:3523-7.
  88. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DYM. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993;151:3460-6.
  89. Perla D, Marmorston J. Suprarenal cortisol hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology 1940;27:367-74.
  90. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-303.
  91. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-9.
  92. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-41.
  93. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl J Med 1984;311:1137-43.
  94. Clemmer TP, Fisher CJ Jr, Bone RC, Slotman GJ, Metz CA, Thomas FO. Hypothermia in the sepsis syndrome and clinical outcome: the methylprednisolone severe sepsis study group. Crit Care Med 1992;20:1395-401.
  95. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 1984;119:537-41.
  96. Briegel J, Jochum M, Gippner-Steppert C, Thiel M. Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001;12:S70-4.
  97. Briegel J, Kellermann W, Forst H, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. Clin Investig 1994;72:782-7.
  98. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998;46:589-97.
  99. Saito T, Takanashi M, Gallagher E, et al. Corticosteroid effect on early b-adrenergic down-regulation during circulatory shock: hemodynamic study and b-adrenergic receptor assay. Intensive Care Med 1995;21:204-10.
  100. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine: mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 2000;68:293-303.
  101. Van Leeuwen HJ, van der Bruggen T, van Asbeck BS, Boereboom FT. Effect of corticosteroids on nuclear factor kB activation and hemodynamics in late septic shock. Crit Care Med 2001;29:1074-7.
  102. Duggan M, Browne I, Flynn C. Adrenal failure in the critically ill. Br J Anaesth 1998;81:468-70.
  103. Schneider AJ, Voerman HJ. Abrupt hemodynamic improvement in late septic shock with physiological doses of glucocorticoids [letter]. Intensive Care Med. 1991;17:436-7.
  104. Benfield K, Cooper J, Scheinkestel CD, Tuxen DV. Relative adrenal insufficiency in patients with septic shock [abstr]. Anaesth Intensive Care 1994;22:215-16.
  105. Briegel J, Forst H, Hellinger H, Haller M. Contribution of cortisol deficiency to septic shock [letter]. Lancet 1991;338:507-8.
  106. Spijkstra JJ, Schreuder WO. Beneficial effects of corticosteroids in septic shock [abstr]. Intensive Care Med 1995;21:S15.
  107. Knighton JD, Woodock TE, Hough M. Adrenal failure in the critically ill [letter]. Br J Anaesth 1999;82:152-3.
  108. Oppert M, Reinicke A, Graf KJ, Barckow D, Frei U, Eckart KU. Plasma cortisol levels before and during "low-dose" hydrocortisone therapy and their relationship to hemodynamic improvement in patients with septic shock. Intensive Care Med 2000;26:1747-55.
  109. Cooperative Study Group. The effectiveness of hydro-cortisone in the management of severe infections. JAMA 1963;183:462-5.
  110. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-32.
  111. Chawla K, Kupfer Y, Goldman I, Tessler S. Hydrocortisone reverses refractory septic shock [abstr]. Crit Care Med 1999;27:A33.
  112. Hoffman SL, Punjabi NH, Kumala S, et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 1984;310:82-8.
  113. Annane D. Effects of the combination of hydrocortisone (HC)-fludro-cortisone (FC) on mortality in septic shock [abstr]. Crit Care Med 2000;28:A46.
  114. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50.
  115. Schelling G, Stoll C, Kapfhammer HP, et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors. Crit Care Med 1999;27:2678-83.
  116. Meduri GU, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. 1995;108: 1315-25.
  117. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998;158:1432-41.
  118. Braude S, Haslam P, Hughes D, Macnaughton P, Evans TW. Chronic adult respiratory distress syndrome: a role for corticosteroids? Crit Care Med 1992;20:1187-9.
  119. Hooper RG, Kearl RA. Established adult respiratory distress syndrome successfully treated with corticosteroids. Chest 1990;97:138-43.
  120. Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Arch Surg 1985;120: 530-5.
  121. Biffl WL, Moore FA, Moore EE, Haenel JB, McIntyre RC, Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg 1995;170:591-6.
  122. Meduri GU, Chinn AJ, Leeper KV, et al. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: patterns of response and predictors of outcome. Chest 1994;105:1516-27.
  123. Varpula T, Pettila V, Rintala E, Takkunen O, Valtonen V. Late steroid therapy in primary acute lung injury. Intensive Care Med 2000;26:526-31.
  124. Keel JBP, Hauser M, Stocker R, Baumann PC, Speich R. Established acute respiratory distress syndrome: benefit of corticosteroid rescue therapy. Respiration 1998;65:258-64.
  125. Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest 1998;114:426-31.
  126. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. JAMA 1998;280:159-65.
  127. ARDS Net. Late steroid rescue study. Available from http://hedwig.mgh.harvard.edu/ardsnet/ards02.html. Accessed June 3, 2002.
  128. Barber AE, Coyle SM, Marano MA, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993;150:1999-2006.
  129. Kim JK, Summer SN, Wood WM, Schrier RW. Role of glucocorticoid hormones in arginine vasopressin gene regulation. Biochem Biophys Res Commun 2001;289:1252-6.
  130. Bernard GR, Vincent JL, Laterre PE, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.